Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-22-031032
Filing Date
2022-11-09
Accepted
2022-11-09 06:20:45
Documents
66
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 1802753
2 ex31-1.htm EX-31.1 10366
3 ex31-2.htm EX-31.2 10399
4 ex32-1.htm EX-32.1 3709
5 ex32-2.htm EX-32.2 4985
6 form10-q_004.jpg GRAPHIC 68844
7 form10-q_002.jpg GRAPHIC 229129
  Complete submission text file 0001493152-22-031032.txt   7370238

Data Files

Seq Description Document Type Size
8 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT lpcn-20220930.xsd EX-101.SCH 39094
9 INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT lpcn-20220930_cal.xml EX-101.CAL 52034
10 INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT lpcn-20220930_def.xml EX-101.DEF 167882
11 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT lpcn-20220930_lab.xml EX-101.LAB 336203
12 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT lpcn-20220930_pre.xml EX-101.PRE 269977
60 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 1171690
Mailing Address 675 ARAPEEN DRIVE, SUITE 202 SALT LAKE CITY X1 84108
Business Address 675 ARAPEEN DRIVE, SUITE 202 SALT LAKE CITY X1 84108 801 994 7383
Lipocine Inc. (Filer) CIK: 0001535955 (see all company filings)

EIN.: 990370688 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36357 | Film No.: 221370562
SIC: 2834 Pharmaceutical Preparations